COPD Exacerbation Follow Up
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40+
SponsorViz.ai, Inc.
About this trial
The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.
Eligibility criteria
Qualifiers
Patients aged 40 years or older at the time of arrival to the emergency department.
Patients with a clinical diagnosis of COPD who present to the emergency department for a moderate or severe COPD exacerbation.
A moderate exacerbation is defined as an acute exacerbation requiring either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics.
A severe exacerbation is defined as an acute exacerbation requiring hospitalization, or observation for >24 hours in emergency department/urgent care facility or resulting in death.
Disqualifiers
Patients on bronchodilator inhaler monotherapy.
Patients leaving against medical advice or expiring during hospitalization.
Patients with tracheostomy.
Patients with advanced cancer.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
485 Participants
are grouped into 3 trial groupsSponsors and collaborators
Source ClinicalTrials.gov